TXP Pharma

TXP Pharma is a Swiss biotechnology company specializing in the development of therapeutic peptides for critical care and inflammatory diseases. The company's core technology focuses on highly selective melanocortin receptor agonists designed to modulate inflammatory responses and provide organ protection. Its lead candidate, TXP-001, is a synthetic peptide being developed to prevent acute kidney injury in patients undergoing cardiac surgery. In 2021, TXP Pharma was acquired by Vifor Pharma for an upfront payment of CHF 100 million to bolster its nephrology and critical care pipeline. Following Vifor's subsequent acquisition by CSL, the assets are now part of the CSL Vifor portfolio. The company's approach leverages the natural protective pathways of the melanocortin system to address high unmet needs in hospital settings.